CalciMedica, Inc. (NASDAQ:CALC) shares rose 6.22% in pre-market trading on Tuesday despite the clinical-stage biopharmaceutical company reporting a wider-than-expected second-quarter loss, as investors focused on progress across its pulmonary hypertension programme and regulatory pipeline.
CalciMedica reported a quarterly loss of $0.45 per share, compared with the analyst estimate for a loss of $0.26 per share.
Net loss for the three months ended June 30, 2026 was $7.7 million, widening from $6.0 million in the same period last year.
Financing supports pulmonary hypertension programme
Investor attention instead appeared to centre on CalciMedica’s clinical development plans and recently completed financing.
The company secured a private placement of up to approximately $49 million, including $15 million in upfront gross proceeds, to help advance its pulmonary hypertension strategy.
“The recent financing supports a pulmonary hypertension strategy, including a Phase 1b proof-of-concept trial using Auxora and the continued development of CM5480 as an oral therapy for chronic use,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
The company expects Phase 1b proof-of-concept data for Auxora in pulmonary arterial hypertension in mid-2027. An investigational new drug submission for CM5480 is also anticipated around the same time.
These milestones give investors clearer upcoming clinical catalysts as CalciMedica expands its development efforts in pulmonary hypertension.
FDA alignment advances Auxora Phase 2b plans
CalciMedica also reported alignment with the U.S. Food and Drug Administration on the design of a Phase 2b trial evaluating Auxora in acute pancreatitis.
The planned study’s primary endpoint will assess whether Auxora can reduce the development of new-onset severe respiratory failure.
For a clinical-stage biotechnology company without commercial revenue, progress toward defined regulatory and clinical milestones remains particularly important to the investment case.
Cash runway extends into second half of 2027
CalciMedica ended June with $18.6 million in cash and cash equivalents, which the company expects will fund operations into the second half of 2027.
Operating expenses moved lower during the quarter. Research and development spending declined to $2.1 million from $4.1 million a year earlier, primarily reflecting reduced preclinical and clinical trial activity.
General and administrative expenses decreased to $1.9 million from $2.6 million.
For the six months ended June 30, CalciMedica reported a net loss of $2.7 million, or $0.16 per share, compared with a loss of $11.0 million, or $0.76 per share, in the first half of 2025.
For investors, the immediate earnings miss is being weighed against a strengthened financing position and a more defined clinical roadmap. Attention now shifts toward execution of the pulmonary hypertension programme, the Auxora Phase 2b programme in acute pancreatitis and the clinical and regulatory milestones expected in 2027.
CalciMedica stock price
